Brokerages Set Altimmune, Inc. (NASDAQ:ALT) PT at $18.80

Altimmune, Inc. (NASDAQ:ALT) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $18.80.

Several research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Thursday, August 22nd. B. Riley reaffirmed a “buy” rating and issued a $20.00 target price on shares of Altimmune in a research note on Monday, August 12th. Piper Sandler reissued an “overweight” rating and issued a $25.00 price target on shares of Altimmune in a research note on Friday, June 21st. Finally, Evercore ISI raised Altimmune to a “strong-buy” rating in a research report on Friday, August 9th.

Altimmune Stock Up 1.3 %

Shares of NASDAQ ALT opened at $6.23 on Friday. Altimmune has a twelve month low of $2.09 and a twelve month high of $14.84. The stock has a market cap of $441.72 million, a price-to-earnings ratio of -3.92 and a beta of 0.08. The company’s fifty day moving average is $6.65 and its 200-day moving average is $7.17.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. The business had revenue of $0.01 million during the quarter. During the same period in the prior year, the business earned ($0.32) EPS. On average, research analysts anticipate that Altimmune will post -0.54 EPS for the current fiscal year.

Insider Transactions at Altimmune

In related news, Director David Drutz sold 16,011 shares of the firm’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the transaction, the director now directly owns 41,958 shares of the company’s stock, valued at approximately $289,510.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its stake in Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after acquiring an additional 335,444 shares during the period. Knoll Capital Management LLC lifted its stake in shares of Altimmune by 183.6% during the 1st quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock worth $5,774,000 after buying an additional 367,219 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Altimmune by 1,282.4% during the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock worth $4,785,000 after acquiring an additional 436,000 shares during the period. Lighthouse Investment Partners LLC bought a new position in shares of Altimmune during the fourth quarter worth approximately $4,493,000. Finally, BBR Partners LLC lifted its holdings in Altimmune by 4.5% during the 2nd quarter. BBR Partners LLC now owns 374,784 shares of the company’s stock worth $2,492,000 after purchasing an additional 16,271 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.